The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma
Lung adenocarcinoma, with increased incidence in the world, exhibits poor prognosis and is usually resistant to conventional chemotherapy due to drug resistance. The enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key role in tumorigenesis and cancer development through ch...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2012-07, Vol.28 (1), p.147-154 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 154 |
|---|---|
| container_issue | 1 |
| container_start_page | 147 |
| container_title | Oncology reports |
| container_volume | 28 |
| creator | Lv, Yijing Yuan, Cunzhong Xiao, Xiaoyan Wang, Xuping Ji, Xuming Yu, Huayun Wu, Zhichun Zhang, Jidong |
| description | Lung adenocarcinoma, with increased incidence in the world, exhibits poor prognosis and is usually resistant to conventional chemotherapy due to drug resistance. The enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key role in tumorigenesis and cancer development through chromatin remodeling in various types of cancer. However, its potential role in lung adenocarcinoma has not been well defined. In this study, the expression of EZH2 was examined in lung adenocarcinoma tissues and cell lines. Most interestingly, EZH2 overexpression was detected in tumor tissue and significantly correlated with histological differentiation, pathological tumor-node-metastasis stage and smoking history, but not with gender or age. Furthermore, EZH2 overexpression was also detected in cisplatin-resistant cancer cells rather than cisplatin-sensitive cells. Short hairpin RNA targeted against EZH2 inhibited cell proliferation and migration, and led to G(2)/M cell cycle arrest and apoptosis in both cisplatin-resistant and cisplatin-sensitive cell lines. Moreover, EZH2 knockdown enhanced cisplatin sensitivity of cisplatin-resistant cells and reduced the expression levels of multidrug resistance-related protein 1. Our study suggests that EZH2 contributes to the progression of lung adenocarcinoma, and the deletion of EZH2 inhibits cancer and resensitizes cells to cisplatin in lung adenocarcinoma. |
| doi_str_mv | 10.3892/or.2012.1787 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1012207806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1012207806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-528d2b1639ed14ce956c917010e8d0a4d3cb23983a9106406e7854b1c2b04f63</originalsourceid><addsrcrecordid>eNpFkM1LwzAYxoMoTqc3z5KL4MHOfDRtc5ThFwy87KCnkqZvt0ibzGQF9a83YVNP7_vAj4eHH0IXlMx4Jdmt8zNGKJvRsioP0AktJc1Yzulh_AmjGefidYJOQ3gnhJWkkMdowpgQLCfFCXpbrgHD58ZDCMZZrGyLg1lZ0xmtrAbsOrxNiF2n6FP-hrAFvHaD690KM2ws7ke7wqoF67Ty2lg3qDN01Kk-wPn-TtHy4X45f8oWL4_P87tFprmQ20ywqmUNLbiEluYapCi0pCWhBKqWqLzlumFcVlxJSoq4GcpK5A3VrCF5V_Aput7Vbrz7GOOyejBBQ98rC24MNY1uGCkrktCbHaq9C8FDV2-8GZT_ilCdXNbO18llnVxG_HLfPDYDtH_wr7wIXO0BFbTqOx8NmfDPCUnjcsl_AJncexs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1012207806</pqid></control><display><type>article</type><title>The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Lv, Yijing ; Yuan, Cunzhong ; Xiao, Xiaoyan ; Wang, Xuping ; Ji, Xuming ; Yu, Huayun ; Wu, Zhichun ; Zhang, Jidong</creator><creatorcontrib>Lv, Yijing ; Yuan, Cunzhong ; Xiao, Xiaoyan ; Wang, Xuping ; Ji, Xuming ; Yu, Huayun ; Wu, Zhichun ; Zhang, Jidong</creatorcontrib><description>Lung adenocarcinoma, with increased incidence in the world, exhibits poor prognosis and is usually resistant to conventional chemotherapy due to drug resistance. The enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key role in tumorigenesis and cancer development through chromatin remodeling in various types of cancer. However, its potential role in lung adenocarcinoma has not been well defined. In this study, the expression of EZH2 was examined in lung adenocarcinoma tissues and cell lines. Most interestingly, EZH2 overexpression was detected in tumor tissue and significantly correlated with histological differentiation, pathological tumor-node-metastasis stage and smoking history, but not with gender or age. Furthermore, EZH2 overexpression was also detected in cisplatin-resistant cancer cells rather than cisplatin-sensitive cells. Short hairpin RNA targeted against EZH2 inhibited cell proliferation and migration, and led to G(2)/M cell cycle arrest and apoptosis in both cisplatin-resistant and cisplatin-sensitive cell lines. Moreover, EZH2 knockdown enhanced cisplatin sensitivity of cisplatin-resistant cells and reduced the expression levels of multidrug resistance-related protein 1. Our study suggests that EZH2 contributes to the progression of lung adenocarcinoma, and the deletion of EZH2 inhibits cancer and resensitizes cells to cisplatin in lung adenocarcinoma.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2012.1787</identifier><identifier>PMID: 22552406</identifier><language>eng</language><publisher>Athens: Spandidos</publisher><subject>Adenocarcinoma - metabolism ; Adenocarcinoma of Lung ; Adult ; Aged ; Antineoplastic Agents - pharmacology ; Apoptosis ; Biological and medical sciences ; Cell Cycle Checkpoints ; Cell Line, Tumor ; Cell Movement ; Cell Nucleus - metabolism ; Cell Proliferation ; Cisplatin - pharmacology ; DNA-Binding Proteins - genetics ; DNA-Binding Proteins - metabolism ; Drug Resistance, Neoplasm ; Enhancer of Zeste Homolog 2 Protein ; Female ; Gene Expression ; Gene Knockdown Techniques ; Humans ; Lung Neoplasms - metabolism ; Male ; Medical sciences ; Middle Aged ; Multidrug Resistance-Associated Proteins - genetics ; Multidrug Resistance-Associated Proteins - metabolism ; Pneumology ; Polycomb Repressive Complex 2 ; RNA Interference ; Transcription Factors - genetics ; Transcription Factors - metabolism ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Oncology reports, 2012-07, Vol.28 (1), p.147-154</ispartof><rights>2015 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-528d2b1639ed14ce956c917010e8d0a4d3cb23983a9106406e7854b1c2b04f63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25912399$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22552406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lv, Yijing</creatorcontrib><creatorcontrib>Yuan, Cunzhong</creatorcontrib><creatorcontrib>Xiao, Xiaoyan</creatorcontrib><creatorcontrib>Wang, Xuping</creatorcontrib><creatorcontrib>Ji, Xuming</creatorcontrib><creatorcontrib>Yu, Huayun</creatorcontrib><creatorcontrib>Wu, Zhichun</creatorcontrib><creatorcontrib>Zhang, Jidong</creatorcontrib><title>The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>Lung adenocarcinoma, with increased incidence in the world, exhibits poor prognosis and is usually resistant to conventional chemotherapy due to drug resistance. The enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key role in tumorigenesis and cancer development through chromatin remodeling in various types of cancer. However, its potential role in lung adenocarcinoma has not been well defined. In this study, the expression of EZH2 was examined in lung adenocarcinoma tissues and cell lines. Most interestingly, EZH2 overexpression was detected in tumor tissue and significantly correlated with histological differentiation, pathological tumor-node-metastasis stage and smoking history, but not with gender or age. Furthermore, EZH2 overexpression was also detected in cisplatin-resistant cancer cells rather than cisplatin-sensitive cells. Short hairpin RNA targeted against EZH2 inhibited cell proliferation and migration, and led to G(2)/M cell cycle arrest and apoptosis in both cisplatin-resistant and cisplatin-sensitive cell lines. Moreover, EZH2 knockdown enhanced cisplatin sensitivity of cisplatin-resistant cells and reduced the expression levels of multidrug resistance-related protein 1. Our study suggests that EZH2 contributes to the progression of lung adenocarcinoma, and the deletion of EZH2 inhibits cancer and resensitizes cells to cisplatin in lung adenocarcinoma.</description><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma of Lung</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Biological and medical sciences</subject><subject>Cell Cycle Checkpoints</subject><subject>Cell Line, Tumor</subject><subject>Cell Movement</subject><subject>Cell Nucleus - metabolism</subject><subject>Cell Proliferation</subject><subject>Cisplatin - pharmacology</subject><subject>DNA-Binding Proteins - genetics</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Drug Resistance, Neoplasm</subject><subject>Enhancer of Zeste Homolog 2 Protein</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Gene Knockdown Techniques</subject><subject>Humans</subject><subject>Lung Neoplasms - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multidrug Resistance-Associated Proteins - genetics</subject><subject>Multidrug Resistance-Associated Proteins - metabolism</subject><subject>Pneumology</subject><subject>Polycomb Repressive Complex 2</subject><subject>RNA Interference</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1LwzAYxoMoTqc3z5KL4MHOfDRtc5ThFwy87KCnkqZvt0ibzGQF9a83YVNP7_vAj4eHH0IXlMx4Jdmt8zNGKJvRsioP0AktJc1Yzulh_AmjGefidYJOQ3gnhJWkkMdowpgQLCfFCXpbrgHD58ZDCMZZrGyLg1lZ0xmtrAbsOrxNiF2n6FP-hrAFvHaD690KM2ws7ke7wqoF67Ty2lg3qDN01Kk-wPn-TtHy4X45f8oWL4_P87tFprmQ20ywqmUNLbiEluYapCi0pCWhBKqWqLzlumFcVlxJSoq4GcpK5A3VrCF5V_Aput7Vbrz7GOOyejBBQ98rC24MNY1uGCkrktCbHaq9C8FDV2-8GZT_ilCdXNbO18llnVxG_HLfPDYDtH_wr7wIXO0BFbTqOx8NmfDPCUnjcsl_AJncexs</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Lv, Yijing</creator><creator>Yuan, Cunzhong</creator><creator>Xiao, Xiaoyan</creator><creator>Wang, Xuping</creator><creator>Ji, Xuming</creator><creator>Yu, Huayun</creator><creator>Wu, Zhichun</creator><creator>Zhang, Jidong</creator><general>Spandidos</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma</title><author>Lv, Yijing ; Yuan, Cunzhong ; Xiao, Xiaoyan ; Wang, Xuping ; Ji, Xuming ; Yu, Huayun ; Wu, Zhichun ; Zhang, Jidong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-528d2b1639ed14ce956c917010e8d0a4d3cb23983a9106406e7854b1c2b04f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma of Lung</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Biological and medical sciences</topic><topic>Cell Cycle Checkpoints</topic><topic>Cell Line, Tumor</topic><topic>Cell Movement</topic><topic>Cell Nucleus - metabolism</topic><topic>Cell Proliferation</topic><topic>Cisplatin - pharmacology</topic><topic>DNA-Binding Proteins - genetics</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Drug Resistance, Neoplasm</topic><topic>Enhancer of Zeste Homolog 2 Protein</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Gene Knockdown Techniques</topic><topic>Humans</topic><topic>Lung Neoplasms - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multidrug Resistance-Associated Proteins - genetics</topic><topic>Multidrug Resistance-Associated Proteins - metabolism</topic><topic>Pneumology</topic><topic>Polycomb Repressive Complex 2</topic><topic>RNA Interference</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>online_resources</toplevel><creatorcontrib>Lv, Yijing</creatorcontrib><creatorcontrib>Yuan, Cunzhong</creatorcontrib><creatorcontrib>Xiao, Xiaoyan</creatorcontrib><creatorcontrib>Wang, Xuping</creatorcontrib><creatorcontrib>Ji, Xuming</creatorcontrib><creatorcontrib>Yu, Huayun</creatorcontrib><creatorcontrib>Wu, Zhichun</creatorcontrib><creatorcontrib>Zhang, Jidong</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lv, Yijing</au><au>Yuan, Cunzhong</au><au>Xiao, Xiaoyan</au><au>Wang, Xuping</au><au>Ji, Xuming</au><au>Yu, Huayun</au><au>Wu, Zhichun</au><au>Zhang, Jidong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>28</volume><issue>1</issue><spage>147</spage><epage>154</epage><pages>147-154</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Lung adenocarcinoma, with increased incidence in the world, exhibits poor prognosis and is usually resistant to conventional chemotherapy due to drug resistance. The enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key role in tumorigenesis and cancer development through chromatin remodeling in various types of cancer. However, its potential role in lung adenocarcinoma has not been well defined. In this study, the expression of EZH2 was examined in lung adenocarcinoma tissues and cell lines. Most interestingly, EZH2 overexpression was detected in tumor tissue and significantly correlated with histological differentiation, pathological tumor-node-metastasis stage and smoking history, but not with gender or age. Furthermore, EZH2 overexpression was also detected in cisplatin-resistant cancer cells rather than cisplatin-sensitive cells. Short hairpin RNA targeted against EZH2 inhibited cell proliferation and migration, and led to G(2)/M cell cycle arrest and apoptosis in both cisplatin-resistant and cisplatin-sensitive cell lines. Moreover, EZH2 knockdown enhanced cisplatin sensitivity of cisplatin-resistant cells and reduced the expression levels of multidrug resistance-related protein 1. Our study suggests that EZH2 contributes to the progression of lung adenocarcinoma, and the deletion of EZH2 inhibits cancer and resensitizes cells to cisplatin in lung adenocarcinoma.</abstract><cop>Athens</cop><pub>Spandidos</pub><pmid>22552406</pmid><doi>10.3892/or.2012.1787</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2012-07, Vol.28 (1), p.147-154 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1012207806 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - metabolism Adenocarcinoma of Lung Adult Aged Antineoplastic Agents - pharmacology Apoptosis Biological and medical sciences Cell Cycle Checkpoints Cell Line, Tumor Cell Movement Cell Nucleus - metabolism Cell Proliferation Cisplatin - pharmacology DNA-Binding Proteins - genetics DNA-Binding Proteins - metabolism Drug Resistance, Neoplasm Enhancer of Zeste Homolog 2 Protein Female Gene Expression Gene Knockdown Techniques Humans Lung Neoplasms - metabolism Male Medical sciences Middle Aged Multidrug Resistance-Associated Proteins - genetics Multidrug Resistance-Associated Proteins - metabolism Pneumology Polycomb Repressive Complex 2 RNA Interference Transcription Factors - genetics Transcription Factors - metabolism Tumors Tumors of the respiratory system and mediastinum |
| title | The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A25%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20expression%20and%20significance%20of%20the%20enhancer%20of%20zeste%20homolog%202%20in%20lung%20adenocarcinoma&rft.jtitle=Oncology%20reports&rft.au=Lv,%20Yijing&rft.date=2012-07-01&rft.volume=28&rft.issue=1&rft.spage=147&rft.epage=154&rft.pages=147-154&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2012.1787&rft_dat=%3Cproquest_cross%3E1012207806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1012207806&rft_id=info:pmid/22552406&rfr_iscdi=true |